-
Rory Curtis joins Symeres Business Development Team
We are happy to have such an experienced biologist on board to work with our many American clients. In this interview, our new colleague, Rory Curtis, will introduce himself and talk about the journey that led him from London to the city of Buffalo in New York state.
-
Symeres CEO Eelco Ebbers Speaks on “Leaders in Life Sciences” Podcast
Symeres CEO Eelco Ebbers recently shared his insights on the renowned “Leaders in Life Sciences” podcast, hosted by Henk Jan Out. Recorded at the Pivot Park in Oss, near our subsidiary Oncolines, the interview delved into various facets of Eelco’s journey, including his educational background in organic chemistry, Symeres’ services and strategy, as well as personal interests such as family and hobbies.
-
Organix: New facility
On March 26th we had the Grand Opening of our brand new, state-of-the-art Organix synthetic and analytical chemistry laboratories in Woburn, just outside Boston MA.
-
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ-1 Subunit of Voltage-Gated Calcium Channel and the μ-Opioid Receptor
In collaboration with WeLab Barcelona, we report the synthesis and biological activity of novel pain therapeutics, which target both Cavα2δ-1 and MOR. One of these disubstituted pyrrolidines demonstrated an analgesic effect in various rodent models of pain, and a lack of unfavorable off-target interactions, showing no evident signs of withdrawal or tolerance. Click on the link below for a short summary of this publication.
Latest patents
-
Compounds and their use as PDE4 activators
Number: WO/2024/038129
-
Compounds and their use as PDE4 activators
Number: WO/2024/038128
-
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same (Organix)
Number: US 2023/0056273 A1
Latest publications
-
Rare Case of Polymorphism in the Binary System of Enantiomers of a Praziquantel Derivative
Article: Org. Process Res. Dev. 2024, XXXX, XXX, XXX-XXX
-
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ-1 Subunit of Voltage-Gated Calcium Channel and the μ-Opioid Receptor
Article: ChemMedChem 2024, e202300473
-
High Target Homology Does Not Guarantee Inhibition: Aminothiazoles Emerge as Inhibitors of Plasmodium falciparum
Article: ACS Infect. Dis. 2024, XXXX, XXX, XXX-XXX
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.